Liquid biopsy for KRAS, NRAS and BRAF mutation testing in advanced colorectal cancer patients: the Argentinean experience

被引：6

作者：

Guettlein, Leandro ^{[1
,3
]}

Luca, Maria R. ^{[2
]}

Esteso, Federico ^{[2
]}

Fresno, Cristobal

Mariani, Javier ^{[2
]}

Pizarro, Mercedes Otero ^{[1
,3
]}

Brest, Esteban ^{[1
]}

Starapoli, Solange ^{[1
,3
]}

Kreimberg, Kevin ^{[1
,3
]}

Teves, Paula ^{[1
,3
]}

Bertelli, Andrea Mendoza ^{[1
]}

Girotti, Maria R. ^{[1
]}

Salanova, Ruben ^{[1
]}

O'Connor, Juan M. ^{[2
]}

机构：

[1] Biomakers SA, Mol Biol Lab, Av Pueyrredon 1777,9 Floor,C1119ACA, Buenos Aires, DF, Argentina

[2] Inst Alexander Fleming, Clin Oncol, Av Cramer 1180,C1426ANZ, Buenos Aires, DF, Argentina

[3] Natl Inst Genom Med, Technol Dev Dept, Mexico City, DF, Mexico

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 29期

关键词：

BRAF; hotspot mutations; KRAS; liquid biopsy; metastatic colorectal cancer; NRAS; oncogene drivers; CIRCULATING TUMOR DNA; PREVALENCE; AMERICAN; SOCIETY; BLOOD;

D O I：

10.2217/fon-2022-0329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To analyze the frequency of KRAS, NRAS and BRAF hotspot mutations in circulating tumor DNA (ctDNA) from patients with metastatic colorectal cancer (mCRC). Methods: Observational, descriptive and retrospective study in mCRC patients with available ctDNA-based genotype of KRAS, NRAS and BRAF. Results: The frequencies of plasma mutations for KRAS, NRAS and BRAF were 34% (+/- 7), 4% (+/- 3) and 4% (+/- 3), respectively. Median overall survival of plasma-tested RAS/BRAF-mutated patients was 26.6 months (95% CI: 14.4-not estimable [NE]), while RAS/BRAF wild-type patients did not reach the median survival during follow-up. Median progression-free survival for RAS/BRAF wild-type and RAS/BRAF-mutated patients was 12 (95% CI: 7-NE) and 4 months (95% CI: 4-NE), respectively. Conclusion: Our work supports the utility of KRAS, NRAS and BRAF analysis in liquid biopsy from mCRC patients.

引用

页码：3277 / 3287

页数：11

共 28 条

[1] RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study [J].

Bachet, J. B. ;

Bouche, O. ;

Taieb, J. ;

Dubreuil, O. ;

Garcia, M. L. ;

Meurisse, A. ;

Normand, C. ;

Gornet, J. M. ;

Artru, P. ;

Louafi, S. ;

Bonnetain, F. ;

Thirot-Bidault, A. ;

Baumgaertner, I ;

Coriat, R. ;

Tougeron, D. ;

Lecomte, T. ;

Mary, F. ;

Aparicio, T. ;

Marthey, L. ;

Taly, V ;

Blons, H. ;

Vernerey, D. ;

Laurent-Puig, P. .

ANNALS OF ONCOLOGY, 2018, 29 (05) :1211-1219

[2] Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona [J].

Baraniskin, Alexander ;

Van Laethem, Jean-Luc ;

Wyrwicz, Lucjan ;

Guller, Ulrich ;

Wasan, Harpreet S. ;

Matysiak-Budnik, Tamara ;

Gruenberger, Thomas ;

Ducreux, Michel ;

Carneiro, Fatima ;

Van Cutsem, Eric ;

Seufferlein, Thomas ;

Schmiegel, Wolff .

EUROPEAN JOURNAL OF CANCER, 2017, 86 :305-317

[3]

Bi FF, 2020, AM J TRANSL RES, V12, P1044

[4] Clinical correlates of circulating cell-free DNA tumor fraction [J].

Bredno, Joerg ;

Lipson, Jafi ;

Venn, Oliver ;

Aravanis, Alexander M. ;

Jamshidi, Arash .

PLOS ONE, 2021, 16 (08)

[5]

cBioPortal, About Us

[6] Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial [J].

Cremolini, Chiara ;

Rossini, Daniele ;

Dell'Aquila, Emanuela ;

Lonardi, Sara ;

Conca, Elena ;

Del Re, Marzia ;

Busico, Adele ;

Pietrantonio, Filippo ;

Danesi, Romano ;

Aprile, Giuseppe ;

Tamburini, Emiliano ;

Barone, Carlo ;

Masi, Gianluca ;

Pantano, Francesco ;

Pucci, Francesca ;

Corsi, Domenico C. ;

Pella, Nicoletta ;

Bergamo, Francesca ;

Rofi, Eleonora ;

Barbara, Cecilia ;

Falcone, Alfredo ;

Santini, Daniele .

JAMA ONCOLOGY, 2019, 5 (03) :343-350

[7] Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series [J].

Deshwar, Amar ;

Margonis, Georgios Antonios ;

Andreatos, Nikolaos ;

Barbon, Carlotta ;

Wang, Jaeyun ;

Buettner, Stefan ;

Wagner, Doris ;

Sasaki, Kazunari ;

Beer, Andrea ;

Loes, Inger Marie ;

Pikoulis, Emmanouil ;

Damaskos, Christos ;

Garmpis, Nikolaos ;

Kamphues, Karsten ;

He, Jin ;

Kaczirek, Klaus ;

Poultsides, George ;

Lonning, Per Eystein ;

Mischinger, Hans Joerg ;

Aucejo, Federico N. ;

Kreis, Martin E. ;

Wolfgang, Christopher L. ;

Weis, Matthew J. .

ANTICANCER RESEARCH, 2018, 38 (05) :2891-2895

[8] Mutation profiling of cancer drivers in Brazilian colorectal cancer [J].

dos Santos, Wellington ;

Sobanski, Thais ;

de Carvalho, Ana Carolina ;

Evangelista, Adriane Feijo ;

Matsushita, Marcus ;

Berardinelli, Gustavo Noriz ;

de Oliveira, Marco Antonio ;

Reis, Rui Manuel ;

Guimaraes, Denise Peixoto .

SCIENTIFIC REPORTS, 2019, 9 (1)

[9] Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations [J].

Egoavil, C. M. ;

Montenegro, P. ;

Soto, J. L. ;

Casanova, L. ;

Sanchez-Lihon, J. ;

Castillejo, M. I. ;

Martinez-Canto, A. ;

Perez-Carbonell, L. ;

Castillejo, A. ;

Guarinos, C. ;

Barbera, V. M. ;

Jover, R. ;

Paya, A. ;

Alenda, C. .

PATHOLOGY, 2011, 43 (03) :228-233

[10] KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients [J].

Ferreira, Carlos Gil ;

Aran, Veronica ;

Zalcberg-Renault, Ilana ;

Victorino, Ana Paula ;

Salem, Jonas H. ;

Bonamino, Martin H. ;

Vieira, Fernando M. ;

Zalis, Mariano .

BMC GASTROENTEROLOGY, 2014, 14

← 1 2 3 →